1. A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma. (23rd June 2021) Authors: Monteith, Bethany E.; Venner, Christopher P.; Cheung, Matthew C.; Pater, Joe; Shepherd, Lois; Richardson, Harriet; Reece, Donna; Gul, Engin; Lalancette, Marc; Castonguay, Vincent; Kukreti, Vishal; Tiedemann, Rodger; Phua, Chai; Bhella, Sita; Dudebout, Jill; Sherry, Max; Yen, Hope; Chen, Bingshu E... Journal: European journal of haematology Issue: Volume 107:Number 3(2021) Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗